Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI318 in Advanced Malignancy
NCT03875157Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Apr 2019
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of reozalimab in advanced cancer (11 arms), sponsored by Innovent Biologics. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events and 1 more. Started Apr 2019; status: completed.
02
Drugs
reozalimab
03
Conditions
advanced cancer
Beyond the preview
Go deeper on NCT03875157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875157.